Impact of combined pregabalin and multimodal analgesia on cancer pain and quality of life in advanced colorectal cancer

Table 1 Comparison of general information between the two groups of patients, n (%)/mean ± SD

Index	Observation group (n = 50)	Control group (n = 50)	χ2/t	P value
Gender			0.16	0.689
Male	28 (56.00)	26 (52.00)
Female	22 (44.00)	24 (48.00)
Age (years)	12.35 ± 4.18	20.46 ± 4.52	2.23	0.028
Disease duration (months)	6.15 ± 2.38	12.58 ± 3.15	0.98	0.328
Sites of tumor metastasis	42.85 ± 5.63	33.67 ± 5.24	0.35	0.951
Liver	23 (46.00)	21 (42.00)
Lung	15 (30.00)	16 (32.00)
Abdominal cavity	8 (16.00)	9 (18.00)
Other	4 (8.00)	4 (8.00)
Baseline NRS score (scores)	26.34 ± 4.15	18.75 ± 3.86	0.38	0.705

NRS: Numerical rating scale.

Table 2 Comparison of pain-related indicators between the two groups of patients before and after intervention, mean ± SD

Index	Group	Before intervention	After intervention	t	P value
NRS score (points)	Observation group (n = 50)	6.8 ± 1.2	2.3 ± 0.8	6.92	< 0.001
	Control group (n = 50)	6.7 ± 1.3	3.7 ± 1.0
Number of pain attacks per day	Observation group (n = 50)	2.8 ± 0.9	0.4 ± 0.3	12.15	< 0.001
	Control group (n = 50)	2.7 ± 1.0	1.5 ± 0.6
Average daily dose of opioids (mg OME)	Observation group (n = 50)	185.3 ± 30.5	85.6 ± 20.3	10.38	< 0.001
	Control group (n = 50)	182.7 ± 29.8	132.4 ± 25.6

P < 0.05 for comparisons before and after intervention within the group; oral morphine milligram equivalents is the daily milligram equivalent of oral morphine. NRS: Numerical rating scale; OME: Oral morphine milligram equivalents.

Table 3 Comparison of quality of life (cancer patient quality of life core scale) scores between the two groups of patients before and after intervention

Dimensions	Group	Before intervention	After intervention	t	P value
Overall health	Observation group (n = 50)	42.3 ± 8.6	68.5 ± 10.2	7.85	< 0.001
	Control group (n = 50)	41.8 ± 8.9	52.4 ± 9.6
E-emotional function	Observation group (n = 50)	50.2 ± 9.3	72.3 ± 9.8	6.52	< 0.001
	Control group (n = 50)	49.7 ± 9.5	58.7 ± 10.1
Cognitive function	Observation group (n = 50)	48.5 ± 10.1	70.6 ± 10.5	6.98	< 0.001
	Control group (n = 50)	48.1 ± 9.8	56.3 ± 9.9
Tired	Observation group (n = 50)	58.6 ± 9.2	32.1 ± 8.4	7.23	< 0.001
	Control group (n = 50)	59.1 ± 9.4	45.6 ± 9.2
Pain	Observation group (n = 50)	65.3 ± 8.7	28.3 ± 7.6	8.65	< 0.001
	Control group (n = 50)	64.9 ± 8.9	42.8 ± 8.7
Insomnia	Observation group (n = 50)	57.8 ± 9.0	30.5 ± 8.2	7.51	< 0.001
	Control group (n = 50)	58.2 ± 9.3	44.3 ± 9.1

P < 0.05 for comparisons before and after intervention within the group; the higher the score of functional and overall health status dimensions and the lower the score of symptom dimension, the better the quality of life.

Table 4 Comparison of the incidence of adverse reactions between the two groups of patients, n (%)

Type of adverse reaction	Observation group (n = 50)	Control group (n = 50)	χ2	P value
Dizziness	12 (24.00)	8 (16.00)	0.98	0.322
Lethargy	10 (20.00)	6 (12.00)	1.15	0.284
Peripheral edema	8 (16.00)	4 (8.00)	1.72	0.190
Constipate	6 (12.00)	18 (36.00)	8.57	< 0.001
Nausea and vomiting	4 (8.00)	14 (28.00)	7.81	0.005
Itchy skin	3 (6.00)	5 (10.00)	0.54	0.463
Overall incidence	23 (46.00)	21 (42.00)	0.16	0.689